Millennium Management
MBVX

Millennium Management’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Millennium Management’s Portfolio MBVX Stock Details MBVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,791
Closed -$46K – 4107
2017
Q1 		$46K Sell
6,791
-3,438
-34% -$29.8K ﹤0.01% 3392
2016
Q4 		$104K Buy
+10,229
New +$117K ﹤0.01% 3186

Other funds holding MBVX

BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BW
Bison Wealth Atlanta, Georgia $454M AUM 22.8% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
DRD
Dennis R. Delaney $282M AUM 16.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management's MBVX Position: Q2 2017 in Review

Millennium Management sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q2 2017, closing a stake of 6,791 shares — an estimated $46K sold.

Millennium Management first reported a position in MBVX in Q4 2016 and held it in 2 quarters. The position peaked at $104K in Q4 2016. 10 funds tracked by Wall St. Rank hold MBVX as of Q2 2017.

  • Millennium Management reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q2 2017 after selling out during the quarter.
  • Millennium Management sold 6,791 MABVAX THERAPEUTICS HLDGS INC shares in Q2 2017, an estimated $46K.
  • Millennium Management first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q4 2016 and held it in 2 quarters.
  • Millennium Management's MABVAX THERAPEUTICS HLDGS INC position peaked at $104K in Q4 2016.
  • 10 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q2 2017.

Based on Millennium Management's 13F filing for Q2 2017, filed 14 Aug 2017.